Recently, great advances in molecular classification and development of new target drugs have occurred in diagnosis and treatment of lung cancer. However, benefit from these progresses is limited to a small number of lung cancer patients. Platinum is known to kill tumor cells through intra- or inter-strand cross links. For decades, it has been in the mainstay of treatment of lung cancer. So far, many studies have suggested that ERCC1 at levels of protein, messenger RNA or germ-line DNA could be a prognostic or predictive biomarker in non-small-cell lung cancer patients treated with platinum doublets, whereas contradictory results have been concurrently reported
